comparemela.com

Latest Breaking News On - Dcph - Page 3 : comparemela.com

Deciphera Pharmaceuticals (NASDAQ:DCPH) Issues Earnings Results, Beats Expectations By $0.04 EPS

Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.04, Briefing.com reports. The business had revenue of $48.30 million during the quarter, compared to analyst estimates of $45.93 million. Deciphera Pharmaceuticals had a […]

United-states
Canada
Matthewl-sherman
Piper-sandler
Stifel-nicolaus
Lazard-asset-management
Tower-research-capital
Jpmorgan-chase-co
Deciphera-pharmaceuticals-inc
Deciphera-pharmaceuticals
Earnings-history-for-deciphera-pharmaceuticals
Deciphera-pharmaceuticals-price-performance

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives $22.56 Consensus Price Target from Analysts

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the […]

China
United-states
Stifel-nicolaus
Piper-sandler
Matthewl-sherman
Lazard-asset-management
Jpmorgan-chase-co
Advisor-group-holdings-inc
Deciphera-pharmaceuticals-inc
Compass-wealth-management
Deciphera-pharmaceuticals-company-profile
Deciphera-pharmaceuticals-stock

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) have been assigned an average rating of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 1 […]

United-states
China
Stevenl-hoerter
Piper-sandler
Stifel-nicolaus
Matthewl-sherman
Securities-exchange-commission
Advisor-group-holdings-inc
Deciphera-pharmaceuticals-price-performance
Compass-wealth-management
Deciphera-pharmaceuticals
Analyst-recommendations-for-deciphera-pharmaceuticals

HC Wainwright Increases Deciphera Pharmaceuticals (NASDAQ:DCPH) Price Target to $30.00

Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) had its target price hoisted by equities research analysts at HC Wainwright from $25.00 to $30.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 152.95% […]

United-states
Matthewl-sherman
Piper-sandler
Stifel-nicolaus
Deciphera-pharmaceuticals
Deciphera-pharmaceuticals-inc
Goldman-sachs-group-inc
Deciphera-pharmaceuticals-stock-down
Vanguard-group-inc
News-ratings-for-deciphera-pharmaceuticals-daily
Hermes-inc
Blackrock-inc

Jonestrading Upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) to "Buy"

Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) was upgraded by equities researchers at Jonestrading from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, Benzinga reports. A number of other equities analysts have also issued reports on DCPH. Stifel Nicolaus upgraded shares of Deciphera Pharmaceuticals from a “hold” rating […]

California
United-states
Thomas-patrick-kelly
Stifel-nicolaus
Piper-sandler
Matthewl-sherman
Analyst-recommendations-for-deciphera-pharmaceuticals
Profund-advisors
Hedge-funds-weigh-in-on-deciphera-pharmaceuticals
Connor-clark-lunn-investment-management-ltd
Alphacentric-advisors
Deciphera-pharmaceuticals-trading-down

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.